 "Dishman Pharma gains post clarification on Clovis issue")
Dishman Pharmaceuticals and Chemicals is trading higher by 5% at Rs 341 on the National Stock Exchange (NSE) after the company has clarified that it has not received any warning from the United States Food and Drug Administration (USFDA) on Clovis issue.
The stock has hit a high of Rs 345 in an intra-day trade and has seen a combined 2.7 million shares changed hands on the counter on the NSE and BSE.
On Tuesday, the stock tanked 14% on news reports that USFDA gives warning letter to Dishman due to Clovis issues.
“The company has not received any USFDA warnings or any communication whatsoever due to Clovis Issue” Dishman Pharma said in a regulatory filing.
Recent news item which appeared in the website-www.moneycontrol.com/ET Now/CNBC dated 17-Nov-2015 are basically with related to Clovis Oncology only and it has not relevance with our company, it added.
The stock has hit a high of Rs 345 in an intra-day trade and has seen a combined 2.7 million shares changed hands on the counter on the NSE and BSE.
On Tuesday, the stock tanked 14% on news reports that USFDA gives warning letter to Dishman due to Clovis issues.
“The company has not received any USFDA warnings or any communication whatsoever due to Clovis Issue” Dishman Pharma said in a regulatory filing.
Recent news item which appeared in the website-www.moneycontrol.com/ET Now/CNBC dated 17-Nov-2015 are basically with related to Clovis Oncology only and it has not relevance with our company, it added.
You’ve reached your limit of {{free_limit}} free articles this month.
Subscribe now for unlimited access.
Already subscribed? Log in
Subscribe to read the full story →*Subscribe to Business Standard digital and get complimentary access to The New York Times
Smart Quarterly
₹900
3 Months
₹300/Month
SAVE 25%
Smart Essential
₹2,700
1 Year
₹225/Month
SAVE 46%
*Complimentary New York Times access for the 2nd year will be given after 12 months
Super Saver
₹3,900
2 Years
₹162/Month
Subscribe
Renews automatically, cancel anytime
Here’s what’s included in our digital subscription plans
Exclusive premium stories online
Over 30 premium stories daily, handpicked by our editors
Complimentary Access to The New York Times
News, Games, Cooking, Audio, Wirecutter & The Athletic
Business Standard Epaper
Digital replica of our daily newspaper — with options to read, save, and share
Curated Newsletters
Insights on markets, finance, politics, tech, and more delivered to your inbox
Market Analysis & Investment Insights
In-depth market analysis & insights with access to The Smart Investor
Archives
Repository of articles and publications dating back to 1997
Ad-free Reading
Uninterrupted reading experience with no advertisements
Seamless Access Across All Devices
Access Business Standard across devices — mobile, tablet, or PC, via web or app
SAVE 25%